Price
$0.6088
Decreased by -7.76%
Dollar Volume
1.44 M
ADR%
16.4
Earnings Report Date (estimate)
Feb 13, 23 (-0.08)
Market Cap.
13.97 M
Shares Float
22.78 M
Shares Outstanding
22.95 M
Beta
0.89
Price / Earnings
-1.00
BPR
23.40
20D Range
0.37 0.87
50D Range
0.23 0.87
200D Range
0.23 2.46
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.18
Decreased by -38.46%
-0.21
Increased by +14.29%
Aug 9, 22 -0.19
Decreased by -18.75%
-0.22
Increased by +13.64%
Jun 28, 22 -0.26
Decreased by -73.33%
-0.14
Decreased by -85.71%
Feb 14, 22 -0.16
Increased by +20.00%
-0.13
Decreased by -23.08%
Nov 9, 21 -0.13
Increased by +13.33%
-0.15
Increased by +13.33%
Aug 9, 21 -0.16
Increased by +27.27%
-0.13
Decreased by -23.08%
Jun 24, 21 -0.15
Increased by +46.43%
-0.20
Increased by +25.00%
Feb 10, 21 -0.20
Increased by +84.50%
-0.16
Decreased by -25.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by -100.00%
-3.81 M
Decreased by -89.62%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-2.91 M
Decreased by -38.54%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 13.12 K
Decreased by -61.69%
-3.79 M
Decreased by -67.26%
Decreased by -28.86 K%
Decreased by -336.56%
Dec 31, 21 17.12 K
Decreased by -97.26%
-2.53 M
Decreased by -3.48%
Decreased by -14.77 K%
Decreased by -3.68 K%
Sep 30, 21 131.97 K
Increased by +N/A%
-2.01 M
Decreased by -13.41%
Decreased by -1.52 K%
Decreased by N/A%
Jun 30, 21 131.97 K
Increased by +N/A%
-2.10 M
Decreased by -48.72%
Decreased by -1.59 K%
Decreased by N/A%
Mar 31, 21 34.23 K
Decreased by -83.44%
-2.26 M
Decreased by -26.93%
Decreased by -6.61 K%
Decreased by -666.49%
Dec 31, 20 624.87 K
Increased by +51.13%
-2.44 M
Decreased by -198.07%
Decreased by -390.94%
Decreased by -97.22%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.